Fuenmayor L D, Vogt M
Br J Pharmacol. 1979 Oct;67(2):309-18. doi: 10.1111/j.1476-5381.1979.tb08681.x.
1 Catalepsy was produced in rats and mice by the subcutaneous injection of either tetrabenazine or the butyrophenone U-32,802A (4'-fluoro-4-{[4-(p-fluorophenyl)-3-cyclohexen-1-yl]amino} butyrophenone hydrochloride). Catalepsy was evaluated by the duration of total immobility on a vertical grid.2 Pretreatment with p-chlorophenylalanine (PCPA) reduced the intensity of catalepsy by 50% or more, whereas its time course remained the same.3 5-Hydroxytryptophan (5-HTP), 10 mg/kg, enhanced the catalepsy induced by U-32,802A or tetrabenazine, provided it was administered soon (45 min) after the neuroleptic; injections at 90 min had no effect. Otherwise untreated rats given this dose of 5-HTP behaved normally on the grid.4 The anticataleptic effect of PCPA was reversed by 5-HTP.5 Measurable changes in 5-hydroxytryptamine (5-HT) metabolism in the rat forebrain accompanied the modification of catalepsy by 5-HTP and PCPA.6 Methysergide (5 mg/kg) given 30 min before the neuroleptics to either mice or rats reduced the catalepsy, assessed 2.5 h after the methysergide. It also prevented the increase in neuroleptic-induced catalepsy following 5-HTP, 10 mg/kg.7 Tryptophan, like 5-HTP, increased the catalepsy seen in mice after U-32,802A and tetrabenazine, and increased the production of 5-hydroxyindol-3-ylacetic acid in the forebrain.8 In the rat, intracerebroventricular injection of physostigmine produced catalepsy which was not modified by methysergide or PCPA but was abolished by atropine. Similarly, in the mouse, catalepsy induced by the subcutaneous injection of pilocarpine was abolished by atropine but not affected by either methysergide or 5-HTP.9 Atropine greatly reduced the catalepsy induced by U-32,802A and tetrabenazine but lowered striatal homovanillic acid (HVA) only after U-32,802A. D,L-DOPA, 20 mg/kg, diminished the cataleptogenic effect of both neuroleptics and raised striatal HVA.10 The results support the view that there is a facilitating or permissive action of 5-HT-containing neurones on neuroleptic-induced catalepsy.
1 通过皮下注射丁苯那嗪或丁酰苯U-32,802A(盐酸4'-氟-4-{[4-(对氟苯基)-3-环己烯-1-基]氨基}丁酰苯)在大鼠和小鼠中诱发僵住症。通过在垂直网格上的完全不动持续时间来评估僵住症。
2 用对氯苯丙氨酸(PCPA)预处理可使僵住症强度降低50%或更多,但其时间进程保持不变。
3 10毫克/千克的5-羟色氨酸(5-HTP)增强了由U-32,802A或丁苯那嗪诱发的僵住症,前提是在给予抗精神病药物后不久(45分钟)给药;90分钟时注射则无作用。否则,给予此剂量5-HTP的未处理大鼠在网格上表现正常。
4 5-HTP可逆转PCPA的抗僵住症作用。
5 大鼠前脑中5-羟色胺(5-HT)代谢的可测量变化伴随着5-HTP和PCPA对僵住症的改变。
6 在给小鼠或大鼠注射抗精神病药物前30分钟给予麦角新碱(5毫克/千克)可减轻僵住症,在给予麦角新碱2.5小时后评估。它还可防止10毫克/千克的5-HTP引起的抗精神病药物诱发的僵住症增加。
7 色氨酸与5-HTP一样,增加了U-32,802A和丁苯那嗪处理后小鼠的僵住症,并增加了前脑中5-羟吲哚-3-乙酸的产生。
8 在大鼠中,脑室内注射毒扁豆碱可诱发僵住症,麦角新碱或PCPA对此无影响,但阿托品可消除该症状。同样,在小鼠中,皮下注射毛果芸香碱诱发的僵住症可被阿托品消除,但不受麦角新碱或5-HTP影响。
9 阿托品可大大减轻由U-32,802A和丁苯那嗪诱发的僵住症,但仅在给予U-32,802A后降低纹状体高香草酸(HVA)。20毫克/千克的D,L-多巴可减弱两种抗精神病药物的致僵住症作用并提高纹状体HVA。
10 结果支持这样一种观点,即含5-HT的神经元对抗精神病药物诱发的僵住症有促进或允许作用。